News: Portfolio 2008

CELLUMEN AND MITSUBISHI TANABE PHARMA CORPORATION COLLABORATE IN DISCOVERY TOXICOLOGY

Partnership will aim to enable earlier discovery of toxicity for drugs in development

Pittsburgh, PA, August 19, 2008 —Cellumen, Inc., a discovery toxicology company, today announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), one of the leading pharmaceutical companies in Japan, to develop panels of biomarkers that identify toxicity
early in the drug development process.

 

“We’re pleased to announce this collaboration with MTPC,” says D. Lansing Taylor, PhD, CEO
of Cellumen. “By working together to develop biomarker panels, we hope to identify toxic
liabilities much earlier in the drug development process than currently exists in the marketplace.
Our ultimate goal is to enable MTPC to prioritize its lead drug series.”

 

Cellumen is focused on decreasing the drug attrition rate due to toxicity. The company’s

CellCiphr® CSB™ Toxicity Profiling Services can identify toxic compounds in late primary
screening through early pre-clinical phases, before entering expensive pre-clinical testing where
the pharmaceutical industry is losing millions of dollars from drugs that do not meet the FDA’s
safety requirements. By integrating optimal cells, panels of functional biomarkers and classifier
software, CellCiphr is able to create a Safety Risk Index for compounds, and help researchers
predict potential rodent or human toxicity earlier than ever before.

 

About Cellumen
Cellumen is the leading innovator in cellular systems biology (CSB™) solutions providing the
most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting
development costs. Cellumen’s CSB solutions are driving Discovery Toxicology by addressing
the full complexity of disease and safety. Leading global organizations, such as the Mayo Clinic,
Hamamatsu Photonics K.K., the EPA, FDA, NIH and top pharmaceutical companies, partner with
Cellumen. Cellumen is a partner company of Safeguard Scientifics. Other investors include
Novitas Capital, the Pittsburgh Life Sciences

 

 

 

Page: 1 2